Company profile

ContinUse Biometrics Ltd.

ContinUse Biometrics Ltd. has 1 AI-enabled medical device on the FDA list. The first decision was on April 1, 2021 and the most recent on April 1, 2021 (Gili Pro BioSensor (also known as Gili BioSensor System)). Its most common review panel is Cardiovascular (1 device).

1AI devices

2021First decision

2021Latest decision

1Specialties

Timeline

April 1, 2021 · De Novo DEN200038Gili Pro BioSensor (also known as Gili BioSensor System) · Cardiovascular · QOK